Plenary Sessions

* Program subject to change

Monday, 4 November8:30 - 10:30WELCOME AND FIRST PLENARYCONFERENCE PROGRAM OVERVIEW FROM PROGRAM COMMITTEE CO-CHAIRSSpeaker

Dorte Gyrd-Hansen, PhD, MSc

University of Southern Denmark, Odense, Denmark

Dorte Gyrd-Hansen is Director of the Danish Centre for Health Economics, DaCHE, and Professor of Health Economics at Department of Public Health, University of Southern Denmark, and at University of Tromsø. Her research interests lie in the intersection of health economics and behavioral economics, with a particular focus on citizens’ preferences for health gains, and patients’ and health professionals’ behavior. She uses register data, survey data an conducts experiments in order to improve our understanding of policy relevant behavioral mechanisms. She is president-elect of the European Health Economics Association, and has previously held professorships at University of Queensland and Copenhagen Business School.

Carole Longson, PhD

Association of the British Pharmaceutical Industry (ABPI), London, United Kingdom

Hans Severens, PhD

Erasmus University, Rotterdam, Netherlands

PRESIDENTIAL ADDRESSSpeaker

Nancy Devlin, PhD

University of Melbourne, Melbourne, VIC, Australia

Nancy J. Devlin is director of the Centre for Health Policy at the University of Melbourne in Australia. Previously, she was director of research at the Office of Health Economics in London. Professor Devlin has more than 30 years’ experience in health economics and health outcomes research and serves as an advisor to international healthcare organizations, both in the public and private sectors. She is past-president of the EuroQol Group. She has published more than 100 peer-reviewed journal articles and a number of books in the field. She served as a director on the ISPOR board of directors from 2015-2017 and is now serving as the Society’s president for the 2019-2020 term.

WELCOME FROM ISPOR CEO/EXECUTIVE DIRECTORSpeaker

Nancy S. Berg

ISPOR, Lawrenceville, NJ, USA

Nancy S. Berg is chief executive officer (CEO) and executive director of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the leading global scientific and educational organization for health economics and outcomes research. Ms. Berg has over 30 years of experience in health care and scientific/technical association leadership, and has been an entrepreneur and business consultant to both commercial and nonprofit organizations. At ISPOR, Ms. Berg is responsible for the Society’s global strategic direction and leadership of the association. She has led the organization, in concert with the Board of Directors, to design and implement a new strategic plan, mission, and vision to guide the Society into the future. Previously, Ms. Berg led the International Society for Pharmaceutical Engineering (ISPE) as president and CEO. ISPE is the world's largest professional society fostering dialogue and education on technical, scientific, and regulatory best practices in the pharmaceutical and biotech industries. During her tenure with ISPE, Ms. Berg was the architect of the Society's Strategic Plan, focusing ISPE's energies and expertise on high-value initiatives related to drug shortages, quality metrics, global manufacturing quality, facility and supply chain issues, and patient experiences in clinical trials. Prior to her role at ISPE, Ms. Berg served as executive director and CEO of the Society of Manufacturing Engineers (SME). She also previously founded a strategic and business development consultancy company. Ms. Berg has been engaged in education and business issues at national and international levels. She has served on many government initiatives involving business, community, development, growth, revitalization, and labor issues. She is a supporter of the Leukemia and Lymphoma Society’s Team in Training Program cycling events and a patron of many other charities. Ms. Berg is a graduate of the University of Michigan-Flint and is married to Timothy Jackson.

FIRST PLENARY SESSION- HEALTHCARE DIGITALIZATION- INSTANT, ON DEMAND, AND ALWAYS CONNECTED

Rapid change is characterizing health care systems now. New technologies, discoveries focusing on ensuring integrated and personalized care, and patient empowerment are influencing the way we prevent, diagnose and treat diseases. Experts say that in the years to come major changes will relate not only to technology (robotics, continuous on- and in-body health sensoring, man-made organs, and AI in healthcare decision support), but also to the way care is organized and delivered (telemedicine, hospital redesign, patient empowerment). In addition, the paradigm of healthcare services is shifting from treating illness to sustaining well-being of individuals for whom values, preferences, and expectations vary, making individualized care even more relevant. Within this wide range of developments, digitalization is considered to be the main driver for the way healthcare systems evolve, even at this very moment. Not only will digital technologies influence communication and collaboration within health care systems, but we will learn and discover from data that will be continuously and instantly available. The panel will explore what the objectives, incentives and aspirations of the new players in digital transformation of healthcare are, how the roles of traditional stakeholders in healthcare are changing, and what needs to be done to strengthen the effectiveness of the change efforts in delivering desired results.

Moderators

Bogi Eliasen

Copenhagen Institute for Futures Studies, Copenhagen, Denmark

Bogi Eliasen is a knowledge broker whose expertise lies in combining various fields of knowledge. He initiated the first population genome project, FarGen 2009 and works with bridging digital health and genomics in the context of the future of personalized health for which he in 2019 received the HIMSS Global Achievement Award.

Speakers

Elena Bonfiglioli

Microsoft, Brussels, Belgium

As regional leader for Microsoft Health and Life Sciences’ business, Elena is responsible to drive go-to-market strategy, strategic partnerships and business development with public health organizations, payors and pharma, working together with a community of over 150+ professionals across the EMEA region. She is very passionate about the opportunity to enable the transformation of the health sector through new digital health experiences powered by Cloud and AI. She is an active advocate and public speaker, invited to represent the approach of Microsoft for Healthcare – see recent interview with HIMSS Media. Elena has been working in the health sector for 15+ years, first in health policy at EU level and then in business development. In July 2017, Elena was elected to the HIMSS Europe Governing Council. Mobilizing a core group of industry innovators, Elena started-off the European Cloud in Health Advisory Council, a vendor-neutral C-level forum aimed to foster cloud-first innovation in the health sector. In 2013, working with a group of leading e-Health partners, Elena led two industry-wide go to market and advocacy positions: the Manifesto for a Healthier Europe and Healthier Cities. From 2007-2012, Elena held the role of Senior Director Health and Education Policy in Europe, when she led the creation of the Employability Alliance aimed to empower 20 Mil people with Skills for New Jobs. Elena started at Microsoft in 2003 as Director of Corporate Affairs and Corporate Responsibility. Before joining Microsoft, Elena worked for CSR Europe as Director of Corporate Programs - in charge of stakeholder engagement and CSR initiatives across member companies; actively contributing to the development of the CSR agenda in Europe. Elena co-founded the European Academy of Business in Society where she served as interim Executive Director. She is a co-founder and Board Member of the Women in Leadership (WiL) Network. Elena started her career as policy advisor for the Italian government and the university of Modena on matters of fiscal policy, socio-economic impact of fiscal reform. She co-developed the model and software used to run fiscal reform simulations at national level. Elena is a founding member of the Centre for Evolutionary Management, a network organization aimed to support executive development programs through meditation.

Alexandra Goncalves, MD, PhD, MMSc, FESC

Philips Healthcare, Cambridge, MA, USA

Alexandra Goncalves is the Philips Chief Medical Officer, Strategy, M&A and Partnerships, a position she has held since June 2019. As an academic cardiologist with a business acumen, she provides functional leadership for clinical innovation and clinical strategy for Philips. Alexandra works closely and collaboratively with business, research and functional leaders across the organization, as well as exploring inorganic growth opportunities. Alexandra has joined Philips in 2016 and worked three years as Sr. Medical Director for the Ultrasound business. She was instrumental for the Cardiovascular Ultrasound business success by leading the evaluation of medical trends, by providing clinical insights and strategic direction, and by developing impactful partnerships through fostering relationships with clinical, scientific, regulatory and marketing leaders worldwide. Alexandra started her career as an academic cardiologist in Portugal and Spain and her past experience includes research in epidemiology and clinical trials in the Cardiovascular Department at the Brigham and Women’s Hospital/ Harvard Medical School (HMS). She earned a Master in Medical Sciences from HMS and while working as a clinical cardiologist, she earned a doctorate degree (PhD). Her work was a driving force towards the refinement of the use of echocardiography in transcatheter structural heart interventions. Alexandra is an internationally recognized thought leader with business acumen and an extensive record of multi-disciplinary medical collaborations, as educator, committee leader, author, and editor. She serves as Affiliate Professor of Medicine in Portugal and has been awarded several prizes, including the prestigious Senior Clinical Research and Career Development Award from HMS and Portuguese Foundation for Science and Technology. Executive Profile

Julian Isla

Microsoft, Foundation 29, Madrid, Spain

Julian Isla is the Chief Scientific Officer of the European Dravet Syndrome Federation, and European organization of patients with Dravet Syndrome. Julian Isla founded Dravet Syndrome Foundation seven years ago. Dravet Syndrome Foundation is committed to find new treatment for Dravet Syndrome, an epileptic encephalopathy having long lasting seizures refractory to treatment as severe developmental delay as main symptoms. Julian is the father of Sergio, a young boy six years old who has Dravet Syndrome. Julian is software engineer by training and he works for Microsoft as full time employee. Despite of not having a neuroscience or medical background he gained the skills to be part of the Orphan Drug Committee at European Medicines Agency (EMA) as patient representative. Julian is also part of the Therapeutic Advisory Group for Eurordis, the biggest organization of rare diseases in Europe. In Spain he is ambassador of the Spanish Rare Diseases Federation and member of Ciberer (Spanish Network for research on rare diseases) scientific advisory group”

Peter Knox, MPP

The Life Raft Group, Wayne, NJ, USA

Peter is responsible for oversight of all research activities at the Life Raft Group (LRG), a non-profit that has been advocating for a rare form of cancer (Gastrointestinal Stromal Tumor, or GIST) for nearly 20 years. In particular, Peter and the LRG have been involved in the production and analysis of Real World Data (RWD) and Real World Evidence (RWE) through a patient registry, web-based side effect management platform, and other data products aimed at both patients and clinicians/researchers, and possess significant experience working with various HEOR professionals in the pharmaceutical industry. Prior to working in patient advocacy, Peter worked for various technology and web firms where he gained valuable knowledge on both the user perspective and how technology can be applied to the current digital health paradigm. A holder of a Masters in Public Policy with a concentration in quantitative methods, economics, and health policy from Rutgers University, Peter is especially proud to be working with ISPOR’s newly formed RWE special interest group, where he will enthusiastically offer his knowledge of the patient and caregiver perspective.

Ernst Kuipers, MD PhD

Erasmus MC University Medical Center, Rotterdam, Netherlands

Ernst trained in Internal Medicine and Gastroenterology. He became professor of Medicine and chair of the Departments of Gastroenterology and Hepatology (2000), Internal Medicine (2006), and Surgery (2012) of Erasmus MC University Medical Center in Rotterdam, the Netherlands. His clinical and research interests included early neoplastic gastrointestinal conditions, and colorectal cancer screening. He is fellow of the American Gastroenterology Association and the World Endoscopy Organization’s regional lead on colorectal cancer screening for Europe and the Middle East. He organized and contributed to various international guidelines on cancer screening. He serves since 2013 as CEO of Erasmus MC, a university medical institute that includes a medical school, research facilities and hospitals. It has 4.500 biomedical students, 17.000 employees and an annual budget of 1.7 billion euro. It is the largest university medical center in the Netherlands. In addition, he chaired the board of the Dutch Federation of University Medical Centers, a group of 8 UMCs with 67.000 employees. He also chairs the Dutch national emergency medicine network, and is member of the Dutch national committee for capacity planning of medical specialists and the Dutch National Health Council.

Rebecca Miksad, MD, MPH

Flatiron Health, New York, NY, USA

Rebecca Miksad is a medical oncologist and health outcomes researcher who serves as senior medical director at Flatiron Health. In this role, Rebecca focuses on generating real-world evidence, establishing regulatory-grade quality standards and contributing to the development of clinically-relevant methods to real-world data evaluation and analyses. Rebecca maintains a clinical practice at Boston Medical Center. A nationally recognized clinician and researcher, Rebecca regularly publishes in leading medical journals, serves on national committees and lectures internationally. Prior to joining Flatiron Health, Rebecca was an assistant professor at Harvard Medical School, senior scientist at the Institute for Technology Assessment at Massachusetts General Hospital, and director of gastrointestinal oncology and gastrointestinal oncology clinical trials at Beth Israel Deaconess Medical Center (BIDMC). Rebecca’s academic research focused on improving cancer treatment decision-making through better characterization of patient outcomes and increasing relevance of clinical trial endpoints. Rebecca earned a BA cum laude in economics from Harvard University and an MD with honors in research from Cornell University. She was a resident in internal medicine at Cornell University/New York-Presbyterian Hospital, and completed hematology and medical oncology fellowships at Harvard Medical School/BIDMC. Rebecca earned a MMS from Harvard Medical School and an MPH in Clinical Effectiveness from the Harvard School of Public Health in clinical effectiveness (with an emphasis on decision science). She also completed a post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT).

Tuesday, 5 November8:45 - 10:30WELCOME AND SECOND PLENARYUPDATE FROM ISPOR CHIEF SCIENCE OFFICERSpeaker

Richard Willke, PhD

ISPOR, Lawrenceville, NJ, USA

Richard J. Willke, PhD is chief science officer of ISPOR, the leading global professional society for health economics and outcomes research. Dr Willke has more than 25 years of experience in the life sciences arena and has specialized in outcomes research in a succession of group leadership roles with Pfizer and its legacy companies. At ISPOR, Dr Willke is responsible for designing and implementing strategic initiatives related to scientific research and content priorities that will advance the Society’s mission of promoting health economics and outcomes research excellence to improve decision making for health globally. Previously, Dr Willke was vice president, Outcomes and Evidence Cluster Lead at Pfizer for its Global Health and Value division. He has also served in a number of leadership roles with affiliated organizations, including the Chair of ISPOR Institutional Council (2010), ISPOR Board of Directors (2007-2009), and Chair of the PhRMA Health Outcomes Committee (2002-2004). Prior to joining industry, Dr Willke served as department director in the Center of Health Policy Research at the American Medical Association and held research and teaching positions at The Ohio State University. Dr Willke earned a PhD and MA in economics from Johns Hopkins University. He has authored more than 80 scholarly publications that examine the science and methodologies of health economics and outcomes research.

SECOND PLENARY SESSION- SHAPING THE DIGITAL HEALTHCARE SYSTEM

It has been anticipated that within 20 years, 90% of all healthcare professionals will require some element of digital and genomics skills in order to work within a transformed, data-driven healthcare environment. The rapidly changing environment requires that transformation of healthcare structures, processes, policies, practices is thought through and implemented already now in order to ensure the quality, sustainability, and fairness of the healthcare system. In this session we will explore how the key ‘actors’ in healthcare systems are adapting to the technological developments in healthcare (e.g. genomics, artificial intelligence, digital and real-time medicine, robotics) to deliver more productive, more effective and more personal care for patients. Each speaker will outline the new policies, processes and skill sets they are developing to deliver this digital healthcare system change. The panel will then debate what it takes to deliver the changes required at pace and at scale for the benefit of patients.

Moderators

Petra Wilson

Health Connect Partners, FTI Consulting, Brussels, Belgium

Health Connect Partners helps clients understand the role European health policy environment for the development and roll out of digital health solutions. In addition to managing Health Connect Partners, Petra is engaged as EU Programme Director for Personal Connected Health Alliance, and also acts as senior advisor on digital health for FTI Consulting. Before setting up Health Connect Partners Petra served as CEO of the International Diabetes Federation; and her prior experience includes eight years in the European Commission in the Digital Health Unit, seven years as Senior Director of Connected Health at Cisco. Prior to these roles she taught healthcare law at Nottingham University, UK

Speakers

Pekka Kahri, MSc

Helsinki University Hopsital, Helsinki, Finland

Pekka Kahri is technology officer at HUS Helsinki University Hospital, which is the biggest public healthcare provider and academic medical center in Finland and one of the leading hospitals in digitalization in Europe. Formerly he has worked as Director of Information Services at THL – National Institute for Health and Welfare, with extensive experience in national health registries and data resources as well as Finland’s national eHealth infrastructure and Kanta services.

Suzanne Schrandt

ExPPect

Thomas Senderovitz

Danish Medicines Agency, HMA Management Group, Copenhagen, Denmark

Dr. Thomas Senderovitz is Director General of the Danish Medicines Agency. He holds several posts in the EU Medicines Regulatory Network, e.g. chair of the Heads of Medicines Agencies Management Group and member of the European Medicines Agency’s Management Board as well as a member of the EU Telematics Management Board. In Denmark, he is member of the Steering Committee of the Center for Regulatory Science, University of Copenhagen, of the Reference Group for the Center of Public Leadership, University of Aarhus, of the Board of the Danish Strategy for Personalized Medicine and of the newly established Data Ethics Council. Thomas is a M.D. from the Faculty of Medicine, University of Copenhagen with more than 26 years’ experience from healthcare, the pharmaceutical industry, biotech, CRO and regulatory authorities. He has held several senior management positions within R&D in PAREXEL International, Grünenthal, UCB and Ferring – in addition, he has founded two biotech companies.

Tristan van Doormaal, MD, PhD

Universitätsspital Zürich, Zurich, Switzerland

Tristan van Doormaal is a vascular and skull base neurosurgeon at the University Hospital Zurich and University Hospital Utrecht. His research focusses on bench to bedside development of new techniques to improve patient outcomes. He is co-inventor of the SELANA technique to perform safe bypass surgeries in the brain and Liqoseal, a patch to prevent cerebrospinal fluid leakage after surgery. He is co-founder of AugmedIT, a startup company aimed at providing surgeon with holograms to better prepare and perform complex surgeries.

WELCOME FROM ISPOR PRESIDENT AND PRESENTATION OF ISPOR BEST CHAPTER AWARDSSpeaker

Nancy Devlin, PhD

University of Melbourne, Melbourne, VIC, Australia

Wednesday, 6 November11:00 - 12:30WELCOME AND THIRD PLENARYTHIRD PLENARY SESSION- BIG HEALTHCARE DATA- ENDLESS OPPORTUNITIES FOR RESEARCH AND LEARNING

Healthcare data vary from discrete coded data elements to images of diagnostic tests to unstructured clinical notes. Such big data present a tremendous opportunity for the measurement and reporting of quality in healthcare. However, such high volume and high-variety information demand innovative forms of information processing to ensure enhanced insight and decision making. Data analytics applications on predictive modeling, population health, and quality measurement are all moving forward quickly. Predictive modeling can identify the high cost, high risk drivers and allows early intervention and patient management. Continuing quality measurement at the individual patient level can enhance personalized medicine and improve the overall effectiveness of treatment. Big data may also prove a useful tool for supplementing RCT data with real-world data in order to improve our evidence base. Finally, the richness of social media data may provide alternative evidence on life style patterns and mental health issues. The opportunities are vast and the challenges are great and new methods are needed to harness the potential for these data to have real impact. The aim of this plenary session is to inspire the audience with examples from the experts who are using these tools not only for research but driving learning at the healthcare system level.

Moderators

Dorte Gyrd-Hansen, PhD, MSc

University of Southern Denmark, Odense, Denmark

Speakers

Laura Hatfield, PhD

Harvard Medical School, Boston, MA, USA

Dr. Hatfield is an Associate Professor of Health Care Policy (Biostatistics) at Harvard Medical School's Department of Health Care Policy. Her methods research centers on trade-offs among multiple outcomes, with an emphasis on hierarchical Bayesian modeling, and causal inference with observational data, particularly difference-in-differences designs. She is faculty co-director of the Health Policy Data Science Lab and co-PI of the Methods Core of the Healthcare Markets and Regulation Lab. Recent honors include the 2018 ISPOR Health Economics and Outcomes Research - Methodology award for her paper on incorporating loss functions in safety surveillance decisions. Dr. Hatfield is the 2019 Chair-Elect of the Health Policy Statistics Section of the American Statistical Association and is serving a three-year term on ENAR's Regional Committee (RECOM). Dr. Hatfield earned her BS in genetics from Iowa State University and her MS and PhD in biostatistics from the University of Minnesota.

Jeremy Rassen, ScD

Aetion, Inc., New York, NY, USA

Dr. Jeremy A. Rassen, ScD, is co-founder and chief scientific officer at Aetion, Inc., a company that provides software to evaluate the effectiveness, safety, and value of medical treatments. At Aetion, Dr. Rassen leads the scientific effort around designing methodology for obtaining and communicating medical evidence from real-world data. Dr. Rassen was formerly an assistant professor of Medicine at the Brigham and Women's Hospital and Harvard Medical School, where he focused on methodology for improved validity and reach of pharmacoepidemiology and comparative effectiveness research, including research into propensity score and instrumental variable methods. Before coming to the Brigham and Women’s Hospital, Dr. Rassen worked in Silicon Valley in numerous computer and software companies, including Hewlett-Packard and Epiphany, Inc. His focus was on high-performance software for the creation and analysis of large marketing databases. Dr. Rassen received his Bachelor’s degree from Harvard College and his Doctorate degree in Epidemiology from the Harvard School of Public Health.

Michal Rosen-Zvi, PhD

IBM Research, The Hebrew University, Jerusalem, Israel

Michal is leading a worldwide team of researchers, expert in AI applied to health data and a local team who focuses on deep learning applied to medical imaging, machine learning and cuasual inference technologies applied to patients data. She joined IBM Research in 2005 and has since led various projects in the area of machine learning and healthcare; Therese are multidisciplinary projects where physicians, data scientists, AI experts and experts from Pharmaceutical companies join forces to analyze post launch patients data. Aside from teaching in various academic forums including courses at Tel-Aviv University and the Hebrew University, Michal has published more than 40 peer-reviewed papers, and serves as a Senior Program Committee member and reviewer at leading machine learning, health informatics, and bioinformatics conferences and journals. Nowadays she is also a visiting professor at the Faculty of Medicine at the Hebrew University. Michal holds a PhD in computational physics and completed her postdoctoral studies at UC Berkeley, UC Irvine, and the Hebrew University in the area of Machine Learning. She serves at various boards such as the committees such as the Israeli national digital health committee and the Impact Advisory Committee of the 8400 health network.

WELCOME FROM ISPOR PRESIDENT AND PRESENTATION OF ISPOR SERVICE AWARDSSpeaker

Nancy Devlin, PhD

University of Melbourne, Melbourne, VIC, Australia

ISPOR EUROPE 2020 ANNOUNCEMENTSpeaker

Nancy S. Berg

ISPOR, Lawrenceville, NJ, USA

ISPOR Europe 2019

2-6 November 2019
Copenhagen, Denmark

Plenary Sessions

The Professional Society for
Health Economics and Outcomes Research

ISPOR Europe 2019

2-6 November 2019Copenhagen, Denmark

Plenary Sessions

2-6 November 2019
Copenhagen, Denmark